Therapeutic Advances in Hematology : Impact Factor & More
eISSN: 2040-6215pISSN: 2040-6207
Open AccessShare this on:
Key Metrics
CiteScore 
0.7
H-Index
32
Impact Factor
< 5
SJR
Q2Hematology
SNIP
0.36
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Therapeutic Advances in Hematology
Therapeutic Advances in Hematology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2300 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Hematology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Therapeutic Advances in Hematology
Real-world US Experience with Voxelotor for Sickle Cell Disease: A Plain Language Summary of the RETRO and PROSPECT studies
- 28 Jul 2026
- Therapeutic Advances in Hematology
Plain language summary: How safe and effective is long-term treatment with intravenous plasminogen concentrate for people with type 1 plasminogen deficiency?
- 24 Jul 2026
- Therapeutic Advances in Hematology
A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab
- 14 Jun 2026
- Therapeutic Advances in Hematology
Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?
- 5 Jun 2026
- Therapeutic Advances in Hematology
Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study
- 27 May 2026
- Therapeutic Advances in Hematology
Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
- 19 May 2026
- Therapeutic Advances in Hematology
Real-world US Experience with Voxelotor for Sickle Cell Disease: A Plain Language Summary of the RETRO and PROSPECT studies
- 28 Jul 2026
- Therapeutic Advances in Hematology
Plain language summary: How safe and effective is long-term treatment with intravenous plasminogen concentrate for people with type 1 plasminogen deficiency?
- 24 Jul 2026
- Therapeutic Advances in Hematology
A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab
- 14 Jun 2026
- Therapeutic Advances in Hematology
Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?
- 5 Jun 2026
- Therapeutic Advances in Hematology
Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study
- 27 May 2026
- Therapeutic Advances in Hematology
Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
- 19 May 2026
- Therapeutic Advances in Hematology
FAQs on Therapeutic Advances in Hematology
How long has Therapeutic Advances in Hematology been actively publishing? 
What is the publishing frequency of Therapeutic Advances in Hematology?
How many articles did Therapeutic Advances in Hematology publish last year?
What is the eISSN & pISSN for Therapeutic Advances in Hematology?
What is Citescore for Therapeutic Advances in Hematology?
What is the H Index for Therapeutic Advances in Hematology ?
What is SNIP score for Therapeutic Advances in Hematology?
What is the SJR for Therapeutic Advances in Hematology?
Who is the publisher of Therapeutic Advances in Hematology?
